Fibrinogen concentrate used for congenital afibrinogenaemia and dysfibrinogenaemia

rhage, acquired coagulopathy, liver disease with bleeding and in obstetric haemorrhage. The product should be licensed for these clinical indications and approved by the HPRA. Fibrinogen, in presence of thrombin, activates FVIII and calcium, which is necessary to convert fibrinogen into stable three

-dimensional fibrin coagula. The IBTS is responsible for the distribution of fibrinogen to users nationwide. IBTS must therefore have a sufficient stock and a stable supply of fibrinogen concentrates to meet patient needs.